How you can make a difference

Events

2nd Annual 901 Club Reunion

See photos from the successful August 21 event.

Upcoming Events

Mark your calendars for:

Save Your Life Car Show

Join Kure It at Cruisin' For a Cure "The Save Your Life Car Show" on September 25th, 7 am - 5 pm, at the Orange County Fair and Event Center in Costa Mesa.

For more information please visit the Cruisin' For a Cure web site.

View photos and success stories about past events!

Link to our Facebook page

KureIt! at Facebook

About the Kure It! Kidney Cancer Research Fund

The Kure It! Kidney Cancer Research Fund is a not-for-profit affiliate fund of the City of Hope National Medical Center. Established in the spring of 2007, the Kure It! Kidney Cancer Research Fund is dedicated entirely to funding kidney cancer research under the direction of Dr. Robert Figlin, Associate Director for Clinical Oncology at the City of Hope in Los Angeles. All donations made to the KIKCRF are tax-deductible under Section 501(c)(3) of the Internal Revenue Code.

Incidence and Mortality Rates of Kidney, Breast, Prostate Cancers

When compared to breast and prostate cancer, kidney cancer has the highest mortality rate, despite having the lowest projected incidence. In the U.S. alone, roughly 25% of kidney cancer patients will lose their battle this year as compared to 23% of breast cancer patients and 12% of prostate cancer patients.

Mortality Ratios for Prostate, Breast, Melanoma & Kidney Cancers

graph of selected cancer mortality rates

And yet, kidney cancer receives approximately 1/17 of the amount of funding as breast cancer and only 1/10 the amount as prostate cancer.

Federal Funding for Prostate, Breast, Melanoma & Kidney Cancers

graph of funding for selected cancers

Interesting Fact:

While melanoma has a slightly higher incidence rate than kidney cancer (59,940 v. 51,190) and lower mortality rate (14% v. 25%), the National Cancer Institute provides over three times as much funding for melanoma research than it does for kidney cancer research ($97,199,000 v. $31,055,000).

(Sources: Incidence and Mortality estimates for 2007 developed by the American Cancer Society based on incidence data from the NCI's Surveillance, Epidemiology, and End Results Program and on death data from the National Center for Health Statistics, Centers for Disease Control and Prevention. Funding figures based on the Fiscal Year 2006 as reported by the Financial Management Branch of the National Cancer Institute.)
/r